Thomas Schinecker, Roche CEO (Georgios Kefalas/EPA-EFE/Shutterstock)

Roivant flips ul­cer­a­tive col­i­tis drug to Roche for $7.1B, less than a year af­ter get­ting the drug from Pfiz­er

Roivant will sell its po­ten­tial block­buster ul­cer­a­tive col­i­tis drug to Roche for $7.1 bil­lion, less than a year af­ter ac­quir­ing it from Pfiz­er for what was ef­fec­tive­ly pen­nies on the dol­lar and af­ter months of news re­ports hint­ing that a deal of that size was in the works.

The Swiss Big Phar­ma nabs a drug that could com­pete with Mer­ck’s $10.8 bil­lion pur­chase of Prometheus Bio­sciences ear­li­er this year and Sanofi’s $1.5 bil­lion pact with Te­va. Their drugs are all TL1A in­hibitors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.